Effect of ADMA levels on severity of erectile dysfunction in chronic kidney disease and other risk factors

---

Atıf İçin Kopyala

GÖKÇEN K., KILIÇARSLAN H., COŞKUN B., ERSOY A., KAYGISIZ O., Kordan Y.

CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, cilt.10, 2016 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 10
• Basım Tarihi: 2016
• Doi Numarası: 10.5489/cuaj.3170
• Dergi Adı: CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Introduction: Hormonal, neurogenic, vasculogenic, and psychogenic impairments, as well as endothelial dysfunction may play a role in erectile dysfunction (ED) in patients with chronic kidney disease (CKD). Asymmetrical dimethylarginine (ADMA) is an inhibitor of nitric oxide, which is the key element of ED. ADMA levels are increased in CKD. We aimed to evaluate the effect of serum ADMA, prolactin, testosterone, and hemoglobin levels on erectile function of patients with CKD and control subjects.